ID: ALA3892377

Max Phase: Preclinical

Molecular Formula: C21H20BrF3N6O2S

Molecular Weight: 557.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=CCN(c1ncccc1CNc1nc(Nc2cccc(Br)c2)ncc1C(F)(F)F)S(C)(=O)=O

Standard InChI:  InChI=1S/C21H20BrF3N6O2S/c1-3-10-31(34(2,32)33)19-14(6-5-9-26-19)12-27-18-17(21(23,24)25)13-28-20(30-18)29-16-8-4-7-15(22)11-16/h3-9,11,13H,1,10,12H2,2H3,(H2,27,28,29,30)

Standard InChI Key:  AZSAXICINIVCFK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 557.40

Molecular Weight (Monoisotopic): 556.0504

AlogP: 4.96

#Rotatable Bonds: 9

Polar Surface Area: 100.11

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.07

CX Basic pKa: 4.18

CX LogP: 4.31

CX LogD: 4.31

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.36

Np Likeness Score: -1.73

References

1. Farand J, Mai N, Chandrasekhar J, Newby ZE, Van Veldhuizen J, Loyer-Drew J, Venkataramani C, Guerrero J, Kwok A, Li N, Zherebina Y, Wilbert S, Zablocki J, Phillips G, Watkins WJ, Mourey R, Notte GT..  (2016)  Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency.,  26  (24): [PMID:27876318] [10.1016/j.bmcl.2016.10.092]

Source

Source(1):

• Scientific Literature